Back to results
US 2024/0110192 A1Published application
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
AssigneeSynlogic Operating Company, Inc.
InventorsDean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Life of this patent
Estimating the term…
Abstract
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Claims18
-44. (canceled)
A bacterium comprising at least one non-native gene or gene cassette for producing tryptophan and tryptamine,
- wherein the at least one non-native gene or gene cassette is operably linked to a fumarate and nitrate reductase (FNR)-responsive promoter.
Dependencies are inferred from the claim text.